Did last month’s episode leave you wanting to learn more about the rapidly developing space of psychedelic compounds’ use in treating psychiatric conditions like Major Depressive Disorder, Generalized Anxiety Disorder and various addiction disorders? Drew & Liv had a feeling you would, so look no further than this episode, where they bring on Doug Drysdale, CEO of Cybin Inc., to discuss his company’s mission and progress in this space. Throughout this episode, you will learn how psilocybin and other psychedelics present a completely different approach to treating depression, the underlying neuroplasticity of mental health disorders, and how a treatment session within this paradigm differs from that of current standard of care. You can learn more about Doug’s and Cybin’s work on Cybin’s website, cybin.com. Additionally, you can follow Drew & Liv on Instagram @scienceinsociety to stay in the know on upcoming episodes, new content, and their ~nearly~ famous science shenanigans.